Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, PT Maja Agung Latexindo Tbk's average EBITDA Per Share Growth Rate was 1052.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of PT Maja Agung Latexindo Tbk was 6.40% per year. The lowest was -33.30% per year. And the median was -13.45% per year.
PT Maja Agung Latexindo Tbk (ISX:SURI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PT Maja Agung Latexindo Tbk 3-Year EBITDA Growth Rate Related Terms
ISX:SURI vs ISRG, BDX, RMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, PT Maja Agung Latexindo Tbk's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Maja Agung Latexindo Tbk 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Maja Agung Latexindo Tbk's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Maja Agung Latexindo Tbk's 3-Year EBITDA Growth Rate falls into.
PT Maja Agung Latexindo Tbk 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.40% mean?
PT Maja Agung Latexindo Tbk (ISX:SURI) has a 3-Year EBITDA Growth Rate of 6.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Maja Agung Latexindo Tbk and its competitors. According to the industry distribution chart, PT Maja Agung Latexindo Tbk ranks #362 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 52.7%.
Is PT Maja Agung Latexindo Tbk's 3-Year EBITDA Growth Rate too high?
PT Maja Agung Latexindo Tbk's current 3-Year EBITDA Growth Rate is 6.40%. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. PT Maja Agung Latexindo Tbk's value of 6.40% is 21% below this industry median. Based on the distribution chart, PT Maja Agung Latexindo Tbk ranks #362 out of 687 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PT Maja Agung Latexindo Tbk has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Maja Agung Latexindo Tbk's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Maja Agung Latexindo Tbk ranks #362 out of 687 companies for 3-Year EBITDA Growth Rate. This places PT Maja Agung Latexindo Tbk in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. PT Maja Agung Latexindo Tbk's value of 6.40% is 21% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Maja Agung Latexindo Tbk's current 3-Year EBITDA Growth Rate of 6.40% is 21% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Maja Agung Latexindo Tbk and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Maja Agung Latexindo Tbk's current 3-Year EBITDA Growth Rate is 6.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Maja Agung Latexindo Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Maja Agung Latexindo Tbk (ISX:SURI) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp108.47, compared to a current price of Rp85.00 — trading 21.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.40% and 21% below the Medical Devices & Instruments industry median of 8.10. PT Maja Agung Latexindo Tbk's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PT Maja Agung Latexindo Tbk (ISX:SURI), the current 3-Year EBITDA Growth Rate is 6.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Maja Agung Latexindo Tbk (ISX:SURI) Overvalued in 2026?
Based on GuruFocus' analysis, PT Maja Agung Latexindo Tbk stock appears to be undervalued.
The current stock price of Rp85.00 is trading 21.6% below its estimated GF Value™ of Rp108.47.
GuruFocus considers PT Maja Agung Latexindo Tbk to be Modestly Undervalued.
Key valuation signals for ISX:SURI:
3-Year EBITDA Growth Rate: 6.40%
GF Value™: Rp108.47 vs. price of Rp85.00 (21.6% below fair value)
Industry Position: 21% below the Medical Devices & Instruments median (#362 of 687)
No single metric tells the full story. See the ISX:SURI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Maja Agung Latexindo Tbk specializes in the production of latex gloves, made from natural rubber, and is a primary choice in the medical and industrial sectors. The company's business includes business of making rubber goods for health support needs, such as contraceptive gloves (birth control)/ condoms, pacifiers and compresses, medical rubber gloves, and urinary catheters (folley catheter). Its segments include Gloves and Concentrated latex.
53GF Score
Get the complete analysis for ISX:SURI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SURI has been successfully added to your 
